Document is current
Any future updates will be listed below
-
Authors
Sieiro Santos, Cristiana https://orcid.org/0000-0003-0889-9877
Del Galdo, Francesco https://orcid.org/0000-0002-8528-2283
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06375005 at ClinicalTrials.govnct06655896 at ClinicalTrials.govDocuments that mention this clinical trial
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct05925803 at ClinicalTrials.govDocuments that mention this clinical trial
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct05878717 at ClinicalTrials.govDocuments that mention this clinical trial
P.260 A phase IIB, open label, randomised trial within cohort (TWiC) of IV anifrolumab in adults with systemic sclerosis. The reascent study
https://doi.org/10.1136/jsrd-2026-sswc.303
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct04440592 at ClinicalTrials.govDocuments that mention this clinical trial
P.113 Heterogeneity in treatment outcomes for systemic sclerosis with or without interstitial lung disease: a systematic literature review
https://doi.org/10.1136/jsrd-2026-sswc.163
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct05270668 at ClinicalTrials.govDocuments that mention this clinical trial
AB1196 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
https://doi.org/10.1136/annrheumdis-2024-eular.1886
AB0855 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN SUBJECTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
https://doi.org/10.1136/annrheumdis-2023-eular.4003
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct06195072 at ClinicalTrials.govDocuments that mention this clinical trial
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct05559580 at ClinicalTrials.govDocuments that mention this clinical trial
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct06375005 at ClinicalTrials.govDocuments that mention this clinical trial
AB0877 TARGETING VASCULOPATHY TO SLOW FIBROSIS IN SYSTEMIC SCLEROSIS (SSC): DESIGN OF A PHASE II STUDY WITH A SOLUBLE GUANYLATE CYCLASE ACTIVATOR (SGCA)
https://doi.org/10.1136/annrheumdis-2023-eular.3765
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct06655896 at ClinicalTrials.govDocuments that mention this clinical trial
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct05925803 at ClinicalTrials.govDocuments that mention this clinical trial
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct05878717 at ClinicalTrials.govDocuments that mention this clinical trial
P.260 A phase IIB, open label, randomised trial within cohort (TWiC) of IV anifrolumab in adults with systemic sclerosis. The reascent study
https://doi.org/10.1136/jsrd-2026-sswc.303
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct04440592 at ClinicalTrials.govDocuments that mention this clinical trial
P.113 Heterogeneity in treatment outcomes for systemic sclerosis with or without interstitial lung disease: a systematic literature review
https://doi.org/10.1136/jsrd-2026-sswc.163
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct05270668 at ClinicalTrials.govDocuments that mention this clinical trial
AB1196 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
https://doi.org/10.1136/annrheumdis-2024-eular.1886
AB0855 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN SUBJECTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
https://doi.org/10.1136/annrheumdis-2023-eular.4003
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
nct06375005 at ClinicalTrials.govDocuments that mention this clinical trial
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
Documents that mention this clinical trial
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
https://doi.org/10.1136/rmdopen-2025-005776
- License Information
